
Halozyme Therapeutics Inc
NASDAQ:HALO

Intrinsic Value
The intrinsic value of one
HALO
stock under the Base Case scenario is
78.96
USD.
Compared to the current market price of 59.77 USD,
Halozyme Therapeutics Inc
is
Undervalued by 24%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Halozyme Therapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Halozyme Therapeutics Inc
Balance Sheet Decomposition
Halozyme Therapeutics Inc
Current Assets | 1.1B |
Cash & Short-Term Investments | 596.1m |
Receivables | 308.5m |
Other Current Assets | 180.8m |
Non-Current Assets | 978.1m |
PP&E | 75m |
Intangibles | 818.7m |
Other Non-Current Assets | 84.5m |
Free Cash Flow Analysis
Halozyme Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Halozyme Therapeutics Inc
Revenue
|
1B
USD
|
Cost of Revenue
|
-159.4m
USD
|
Gross Profit
|
855.9m
USD
|
Operating Expenses
|
-304.4m
USD
|
Operating Income
|
551.5m
USD
|
Other Expenses
|
-107.4m
USD
|
Net Income
|
444.1m
USD
|
HALO Profitability Score
Profitability Due Diligence
Halozyme Therapeutics Inc's profitability score is 83/100. The higher the profitability score, the more profitable the company is.

Score
Halozyme Therapeutics Inc's profitability score is 83/100. The higher the profitability score, the more profitable the company is.
HALO Solvency Score
Solvency Due Diligence
Halozyme Therapeutics Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.

Score
Halozyme Therapeutics Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HALO Price Targets Summary
Halozyme Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
HALO
is 69.11 USD
with a low forecast of 55.55 USD and a high forecast of 81.9 USD.
Dividends
Current shareholder yield for HALO is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
HALO
stock under the Base Case scenario is
78.96
USD.
Compared to the current market price of 59.77 USD,
Halozyme Therapeutics Inc
is
Undervalued by 24%.